Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 2,427Hepatocellular Carcinoma Treatment and PrognosisHepatitis B Virus StudiesColorectal Cancer Treatments and Studies

The DOI matches its Crossref record; 195 of the 195 references it cites were found in a registry or an index.

Hepatocellular carcinoma

Vogel, Arndt, Meyer, Tim, Sapisochin, Gonzalo, Salem, Riad, Saborowski, Anna·2022·The Lancet

Abstract

Hepatocellular carcinoma is one of the most common cancers worldwide and represents a major global health-care challenge. Although viral hepatitis and alcohol remain important risk factors, non-alcoholic fatty liver disease is rapidly becoming a dominant cause of hepatocellular carcinoma. A broad range of treatment options are available for patients with hepatocellular carcinoma, including liver transplantation, surgical resection, percutaneous ablation, and radiation, as well as transarterial and systemic therapies. As such, clinical decision making requires a multidisciplinary team that longitudinally adapts the individual treatment strategy according to the patient's tumour stage, liver function, and performance status. With the approval of new first-line agents and second-line agents, as well as the establishment of immune checkpoint inhibitor-based therapies as standard of care, the treatment landscape of advanced hepatocellular carcinoma is more diversified than ever. Consequently, the outlook for patients with hepatocellular carcinoma has improved. However, the optimal sequencing of drugs remains to be defined, and predictive biomarkers are urgently needed to inform treatment selection. In this Seminar, we present an update on the causes, diagnosis, molecular classification, and treatment of hepatocellular carcinoma.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)01200-4

Cites

195 of 195 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 195 references

Cited by

See all 2,427

Metadata

Authors
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A.
Affiliations
  • Medizinische Hochschule Hannover (DE)
  • The Royal Free Hospital (GB)
  • Northwestern University (US)
Corresponding author
Vogel, Arndt
Venue
The Lancet
Publisher
Elsevier BV
Published
2022-10
Volume
400
Issue
10360
Pages
1345-1362
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4294838953
Cited by
2,427
References
195
Citations by year
2026: 501 · 2025: 749 · 2024: 769 · 2023: 386 · 2022: 17
FWCI
83.32
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Keywords
hepatocellular carcinoma, non-alcoholic fatty liver disease, viral hepatitis, alcohol, liver transplantation, surgical resection, percutaneous ablation, radiotherapy, transarterial therapy, systemic therapy, immune checkpoint inhibitors, predictive biomarkers, treatment sequencing, molecular classification, prognosis
MeSH terms
Immune Checkpoint Inhibitors, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Liver Transplantation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatocellular carcinoma. https://app.cochat.ai/papers/10.1016/s0140-6736(22)01200-4
The paper
Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022). Hepatocellular carcinoma. The Lancet. https://doi.org/10.1016/s0140-6736(22)01200-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.